Novo Nordisk A/S (NYSE:NVO) Shares Sold by Transatlantique Private Wealth LLC

Transatlantique Private Wealth LLC trimmed its holdings in shares of Novo Nordisk A/S (NYSE:NVO) by 6.8% during the second quarter, according to its most recent Form 13F filing with the SEC. The firm owned 5,976 shares of the company’s stock after selling 433 shares during the period. Transatlantique Private Wealth LLC’s holdings in Novo Nordisk A/S were worth $833,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also modified their holdings of the stock. First PREMIER Bank acquired a new position in Novo Nordisk A/S during the 1st quarter valued at about $25,000. 1620 Investment Advisors Inc. acquired a new position in shares of Novo Nordisk A/S during the second quarter valued at approximately $25,000. Dixon Mitchell Investment Counsel Inc. bought a new stake in Novo Nordisk A/S during the first quarter worth approximately $26,000. Orion Capital Management LLC acquired a new stake in Novo Nordisk A/S in the first quarter worth approximately $26,000. Finally, Gilliland Jeter Wealth Management LLC boosted its stake in Novo Nordisk A/S by 200.0% during the 2nd quarter. Gilliland Jeter Wealth Management LLC now owns 180 shares of the company’s stock valued at $26,000 after purchasing an additional 120 shares in the last quarter. 11.54% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on NVO. Cantor Fitzgerald restated an “overweight” rating and issued a $160.00 price objective on shares of Novo Nordisk A/S in a report on Monday, September 16th. BMO Capital Markets reduced their price objective on shares of Novo Nordisk A/S from $170.00 to $160.00 and set an “outperform” rating for the company in a research report on Thursday, August 8th. Argus boosted their target price on shares of Novo Nordisk A/S from $125.00 to $160.00 and gave the stock a “buy” rating in a report on Monday, June 10th. The Goldman Sachs Group assumed coverage on shares of Novo Nordisk A/S in a research note on Thursday, May 30th. They set a “buy” rating and a $156.00 target price for the company. Finally, StockNews.com upgraded shares of Novo Nordisk A/S from a “buy” rating to a “strong-buy” rating in a research report on Wednesday. One analyst has rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the company presently has an average rating of “Buy” and an average price target of $145.17.

Novo Nordisk A/S Price Performance

NVO stock opened at $127.51 on Friday. Novo Nordisk A/S has a one year low of $86.96 and a one year high of $148.15. The firm has a 50-day moving average of $133.13 and a two-hundred day moving average of $133.20. The firm has a market capitalization of $572.21 billion, a PE ratio of 43.97, a P/E/G ratio of 1.48 and a beta of 0.42. The company has a current ratio of 0.94, a quick ratio of 0.75 and a debt-to-equity ratio of 0.46.

Novo Nordisk A/S (NYSE:NVO) last issued its quarterly earnings results on Wednesday, August 7th. The company reported $0.65 EPS for the quarter, missing the consensus estimate of $0.71 by ($0.06). Novo Nordisk A/S had a net margin of 34.86% and a return on equity of 87.43%. The firm had revenue of $9.82 billion during the quarter, compared to analysts’ expectations of $9.91 billion. On average, analysts forecast that Novo Nordisk A/S will post 3.11 earnings per share for the current year.

Novo Nordisk A/S Cuts Dividend

The firm also recently declared a semi-annual dividend, which was paid on Monday, August 26th. Stockholders of record on Friday, August 16th were issued a dividend of $0.5126 per share. The ex-dividend date was Friday, August 16th. This represents a dividend yield of 0.7%. Novo Nordisk A/S’s dividend payout ratio is 24.83%.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.